Training inhibitory control in adolescents with elevated attention deficit hyperactivity disorder traits: a randomised controlled trial of the Alfi Virtual Reality programme.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
20 09 2022
Historique:
entrez: 20 9 2022
pubmed: 21 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

Attention deficit hyperactivity disorder (ADHD) is characterised by significant deficits in attention and inhibition. These deficits are associated with negative sequelae that emerge in childhood and often continue throughout adolescence. Despite these difficulties adolescents with ADHD often demonstrate poor treatment compliance with traditional interventions (eg, psychostimulant medication). Virtual reality (VR) presents an innovative means of delivering engaging cognitive interventions for adolescents with ADHD and offers the potential to improve compliance with such interventions. The current parallel, randomised controlled trial aims to evaluate the effects of a VR intervention (Alfi) designed to improve inhibition in adolescents with ADHD. A sample of 100 adolescents (aged 13-17) with elevated ADHD symptoms will be recruited from secondary schools and ADHD organisations located in the state of Victoria, Australia. Participants will be randomly assigned to either an 8-week VR intervention or a usual care control. The VR intervention involves the completion of 14 sessions, each 20 min in duration. Participants will complete computerised assessments of inhibition and risk-taking preintervention and immediately postintervention. Parents/guardians will complete online questionnaires about their child's ADHD symptoms and social functioning at each of these timepoints. The primary outcome is change in inhibition performance in adolescents who received the intervention from preintervention to postintervention compared with adolescents in the control condition. Secondary outcomes include change in risk-taking, ADHD symptoms and social functioning in adolescents who received the intervention from preintervention to postintervention compared with adolescents in the control condition. If the intervention is shown to be effective, it may offer a supplementary approach to traditional interventions for adolescents with ADHD experiencing inhibitory control difficulties. This trial has ethics approval from the Monash University Human Research Ethics Committee (HREC) (21530) and the Victorian Department of Education and Training HREC (2020_004271). Results will be disseminated through peer-reviewed journals, conference proceedings and community activities. Individual summaries of the results will be provided to participants on request. ACTRN12620000647932.

Identifiants

pubmed: 36127121
pii: bmjopen-2022-061626
doi: 10.1136/bmjopen-2022-061626
pmc: PMC9490587
doi:

Substances chimiques

Central Nervous System Stimulants 0

Banques de données

ANZCTR
['ACTRN12620000647932']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e061626

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Ann Med. 2001 Jul;33(5):358-70
pubmed: 11491195
Korean J Pediatr. 2017 Nov;60(11):337-343
pubmed: 29234356
J Child Fam Stud. 2011 Apr;20(2):149-156
pubmed: 21475713
Braz J Med Biol Res. 2015 Nov;48(11):965-72
pubmed: 26313140
BMC Med Res Methodol. 2013 Jul 16;13:92
pubmed: 23855337
Child Neuropsychol. 2017 Aug;23(6):692-712
pubmed: 27258210
Dev Neuropsychol. 2002;21(1):93-111
pubmed: 12058837
Neurosci Biobehav Rev. 2009 May;33(5):631-46
pubmed: 18835296
J Anxiety Disord. 2003;17(6):605-25
pubmed: 14624814
Int J Clin Health Psychol. 2018 Sep-Dec;18(3):254-263
pubmed: 30487931
Child Adolesc Psychiatr Clin N Am. 2014 Oct;23(4):807-24
pubmed: 25220088
Neurotherapeutics. 2012 Jul;9(3):490-9
pubmed: 22976615
Dev Cogn Neurosci. 2013 Apr;4:16-28
pubmed: 23219490
J Abnorm Child Psychol. 2015 Jan;43(1):133-47
pubmed: 24943056
J Marital Fam Ther. 1989 Jul;15(3):259-69
pubmed: 21118457
J Atten Disord. 2021 Jan;25(1):105-114
pubmed: 29771172
BMJ Open. 2022 Jun 16;12(6):e055385
pubmed: 35710251
J Neurophysiol. 2007 Mar;97(3):2480-9
pubmed: 17251361
BMC Med Res Methodol. 2017 Dec 6;17(1):162
pubmed: 29207961
Child Neuropsychol. 2007 Jul;13(4):363-81
pubmed: 17564852
Cereb Cortex. 2016 Jan;26(1):12-22
pubmed: 25085883
Fam Process. 2002 Winter;41(4):723-31
pubmed: 12613127
Trends Cogn Sci. 2008 Nov;12(11):418-24
pubmed: 18799345
Neurology. 2019 Aug 6;93(6):e599-e610
pubmed: 31315973
J Clin Child Adolesc Psychol. 2007 Mar;36(1):106-11
pubmed: 17206886
Biol Psychiatry. 2011 Jun 15;69(12):e55-68
pubmed: 20932513
PLoS One. 2015 Oct 21;10(10):e0140383
pubmed: 26488166
Arch Dis Child. 2005 Oct;90(10):1010-5
pubmed: 16177156
J Psychopathol Behav Assess. 2010 Sep;32(3):373-384
pubmed: 20700377
PLoS One. 2020 Nov 30;15(11):e0241352
pubmed: 33253237
Front Psychol. 2020 Jan 14;10:2983
pubmed: 32010026
J Child Psychol Psychiatry. 2019 Sep;60(9):988-997
pubmed: 30908652
Child Neuropsychol. 2009 Mar;15(2):120-35
pubmed: 18608217
J Child Psychol Psychiatry. 2018 May;59(5):586-595
pubmed: 29052841
Hum Brain Mapp. 2014 Sep;35(9):4415-27
pubmed: 24532023
Lancet Psychiatry. 2018 Sep;5(9):727-738
pubmed: 30097390
Aust N Z J Psychiatry. 2009 Aug;43(8):722-30
pubmed: 19629793
J Neurophysiol. 2006 Jun;95(6):3371-83
pubmed: 16495356
J Child Psychol Psychiatry. 2013 Sep;54(9):996-1004
pubmed: 23574361
Elife. 2019 Apr 29;8:
pubmed: 31033438
Eur J Neurosci. 2017 Jun;45(12):1512-1523
pubmed: 28449195
Hum Brain Mapp. 2013 Sep;34(9):2015-24
pubmed: 22359406
Arch Clin Neuropsychol. 2002 Oct;17(7):643-62
pubmed: 14591848
Clin Neurophysiol. 2005 Jun;116(6):1455-63
pubmed: 15978508
Br J Psychiatry. 2009 Mar;194(3):204-11
pubmed: 19252145
PLoS One. 2010 Nov 04;5(11):e13848
pubmed: 21079814
Psychol Sci. 2008 Nov;19(11):1146-53
pubmed: 19076487
J Atten Disord. 2020 Jun;24(8):1148-1155
pubmed: 29562848
Emotion. 2007 May;7(2):336-53
pubmed: 17516812
Res Dev Disabil. 2018 Jan;72:166-178
pubmed: 29156389
J Cogn Neurosci. 2009 Jun;21(6):1193-203
pubmed: 18702592
Neuropsychology. 2010 Sep;24(5):637-51
pubmed: 20804252
Hum Brain Mapp. 2016 Dec;37(12):4706-4717
pubmed: 27489078
Dev Neurorehabil. 2019 Aug;22(6):431-436
pubmed: 29771624
Psychol Assess. 2007 Mar;19(1):107-18
pubmed: 17371126
Exp Neurol. 2019 Aug;318:78-91
pubmed: 31055004
J Child Psychol Psychiatry. 2014 Mar;55(3):292-300
pubmed: 24261515

Auteurs

Erin McKay (E)

Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia Erin.McKay@monash.edu.

Hannah Kirk (H)

Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.

James Coxon (J)

Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.

Danielle Courtney (D)

Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.

Mark Bellgrove (M)

Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.

Aurina Arnatkeviciute (A)

Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.

Kim Cornish (K)

Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH